Blu – Pagina 294 – AMD

Blu

Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.

Settembre 20, 2017

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT-1): 24 Week Results From a Multicentre, Double-Blind, Phase 3, Randomised Controlled Trial

Dandona P, Mathieu C, Phillip M
The Lancet Diabetes & Endocrinology. Pub. online 14 September 2017

Leggi

Settembre 20, 2017

SGLT2 Inhibitors in Type 1 Diabetes: Knocked Down, But Up Again?

Petrie JR
The Lancet Diabetes & Endocrinology. Pub. online 14 September 2017

Leggi

Settembre 20, 2017

Expanding Treatment Options for Improving Health Outcomes in Type 1 Diabetes

Garg SK
Diabetes Technology & Therapeutics. Pub. online September 2017

Leggi

Settembre 20, 2017

Adult-Onset Autoimmune Diabetes: Current Knowledge and Implications for Management

Buzzetti R, Zampetti S and Maddaloni E
Nature Reviews Endocrinology. Pub. online 08 September 2017

Leggi

Settembre 20, 2017

FDA Approval of Nonadjunctive Use of Continuous Glucose Monitors for Insulin Dosing. A Potentially Risky Decision

Shapiro AR
JAMA. Pub. online September 14, 2017

Leggi

Settembre 20, 2017

Continuous Glucose Monitoring in Pregnant Women With Type 1 Diabetes

Garg SK, Polsky S
The Lancet. Pub.online15 September 2017

Leggi

Settembre 20, 2017

Risk of Atrial Fibrillation in People With Type 1 Diabetes Compared With Matched Controls From The General Population: A Prospective Case-Control Study

Dahlqvist S, Rosengren A, and Gudbjörnsdottir S
The Lancet Diabetes & Endocrinology. 2017;5(10):799-807

Leggi

Settembre 20, 2017

Is Atrial Fibrillation Another Manifestation of Organ Damage in Diabetes?

Miyazawa K and Lip GYH
The Lancet Diabetes & Endocrinology. 2017;5(10):761-2

Leggi

Settembre 14, 2017

Effects on the Incidence of Cardiovascular Events of the Addition of Pioglitazone Versus Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled with Metformin (TOSCA.IT): A Randomised, Multicentre Trial

Vaccaro O, Masulli M, Nicolucci A, et al. for Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group
Lancet Diabetes Endocrinol. Pub. online 13 September 2017

Leggi

Settembre 14, 2017

Pioglitazone Versus Sulfonylureas: Cardiovascular Outcomes with Older Diabetes Drugs

Fonseca VA, Lovre D
Lancet Diabetes Endocrinol. Pub. online 13 September 2017

Leggi